Outcome of Board meeting inter alia for considering and approving Unaudited Financial Results for Quarter-1 of F.Y. 2026-27, ended on June 30, 2026.

OrchidPharm~~ -- A DhanukaGroup Company ------------------------------------ August 14, 2026 National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Dalal Bandra (E), Mumbai-400051 Street, Fort, Mumbai-400001 Symbol: ORCHPHARMA Scrip Code: 524372 Subject: Outcome of Board Meeting - Orchid Pharma Limited ("the Company") Dear Sir/Madam, With reference to the captioned subject and pursuant to Regulation 30 read with Part A Para A of Schedule III and Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), as amended read with SEBI Circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, SEBI Master Circular no. SEBI/ HO/49j14/14(7)2025-CFD-POD2/I/3762/2026, dated January 30, 2026 and in continuation to the prior intimation given by the Company on August 11, 2026 for scheduling the Board Meeting, we would like to inform you that the Board of Directors of the Company at its meeting held today i.e. August 14, 2026 (commenced at 14:00 P.M. (1ST) and concluded at 18: 15 P.M. (1ST) has inter-alia considered and approved unaudited Limited Reviewed Financial Results (Standalone & Consolidated) of the Company for the Quarter-I of Financial Year 2026-27 ended on June 30, 2026, along with the auditors' review reports issued on the same by M/s. Singhi & Co., Statutory Auditors of the Company. You are requested to take the above intimations on record. p. yya Company Secreta , Mem. No.- F10698 Encl. as above +91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994 Registered Office: Corporate Office: Orchid Pharma Limited 15th Floor, Tower 1, DLF Corporate Greens, Sector 74A, Plot Nos. 121-128, 128A-133, 138-151,159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India. Orchid Pharma Limited Regd. Office: Plot Nos. 121 -128, 128A -133,138 -151,159 -164, SIDCO Industrial Estate, Alathur, Chengalpattu District-603110, Tamil Nadu, India Ph. +91 -44 -2744 4471 -78 Email id: corporate@orchidpharma.com Website: www.orchidpharma.com CIN : L24222TN1992PLC022994 Statement of Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026 (All amounts are in lakhs of Indian Rupees, unless otherwise stated) S. No. Particulars Standalone financial results Consolidated financial results For the quarter ended For the year For the quarter ended Forthe year ended ended June 30, 2026 March 31, 2026 June 30, 2025 March 31, 2026 June 30, 2026 March 31, 2026 June 30, 2025 March 31, 2026 (Unaudited) Revised Revised Revised (Unaudited) Revised Revised Revised (Audited) (Unaudited) (Audited) (Audited) (Unaudited) (Audited) (Refer (Refer Note 6 & 7) (Refer Note 7) (Refer Note 7) (Refer Note 6 & 7) (Refer Note 7) Note 7) tncome from Operations 1 Net Sales I Income from operations 30,417.13 36,832.71 26,318.58 1,23,277.84 30417.13 36,832.71 26,318.58 123277.84 2 Other Income 1,004.72 1,372.81 1,605.26 5,648.69 182.84 777.37 1,156.98 3641.83 3 Tolallncome (1+2) 31,421.85 38,205.52 27,923.84 1,28,926.53 30,599.97 37,610.08 27,475.56 1,26,919.67 4 Expenses Cost of materials consumed 20.642.20 20,983.93 20,369.78 77,139.16 20642.2 20,983.93 20,369.78 77139.16 Changes in inventories of raw material, work-in-progress, stock-in-trade (272.47) 3,512.34 (2.109.47) 7,138.39 (272.47) 3,512.34 (2,109.47) 7138.39 and finished goods Purchases of Stock in trade 60.65 47.59 78.79 168.72 60.65 47.59 78.79 168.72 Employee benefit expenses 2.675.81 2,633.08 2,769.80 11,432.05 2803.79 2,761.75 2,769.80 11765.46 Finance costs 221.23 194.97 228.48 896.15 223.02 196.39 228.48 898.43 Depreciation and amortization expense 1,090.16 1,118.44 1,053.46 4,335.60 1094.91 1,090.31 1,053.46 4324.63 Other expenses 5,810.55 6.426.86 5,773.54 23,621.17 5782.92 6.511.15 5,773.88 23708.71 Total Expenses 30,228.13 34,917.21 28,164.38 1,24,731.24 30,335.02 35,103.46 28,164.72 1,25,143.50 5 Profit I (Loss) before exceptional items and lax (3-4) 1,193.72 3,288.31 (240.54) 4,195.29 264.95 2,506.62 (689.16) 1,776.17 6 Exceptional items (refer Note no.3) (22.02) (733.29) (22.02) (733.29) 7 Profit I (Loss) before tax (5+6) 1,193.72 3,266.29 (240.54) 3,462.00 264.95 2,484.60 (689.16) 1,042.88 8 Tax expense Current tax Tax adjustments of earliear years Deferred tax 7.23 0.17 (19.16) TolalT ax Expenses 7.23 0.17 (19.16) 9 Profit I (Loss) forthe period before share of profit of Associates (7- 1,193.72 3,266.29 (240.54) 3,462.00 257.72 2,484.43 (689.16) 1,062.04 Orchid Pharma Limited Statement of Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026 (Contd ... ) S. No. Particulars Standalone financial results Consolidated financial results For the quarter ended Forthe For the quarter ended Forthe year ended year ended June 30, 2026 March 31, 2026 June 30, 2025 March 31, 2026 June 30, 2026 March 31, 2026 June 30, 2025 March 31, 2026 (Unaudited) Revised Revised Revised (Unaudited) Revised Revised Revised (Audited) (Unaudited) (Audited) (Audited) (Unaudited) (Audited) (Refer (Refer Note 6 & 7) (Refer Note 7) (Refer Note 7) (Refer Note 6 & 7) (Refer Note 7) Note 7) 10 Profit I (Loss) for the period before share of profit of Associates 1,193.72 3,266,29 (240,54) 3,462,00 257,72 2,484,43 (689,16) 1,062,04 11 Add: Share of ProfiU (Loss) of Associates 64.72 99.51 119.94 (66.13) 12 Profit I (Loss) forthe period (10+11) 1,193,72 3,266,29 (240,54) 3,462,00 322,44 2,583,94 (569,22) 995,91 13 Other comprehensive income, net of income tax a) (i) items that will not be reclassified to profil or loss 0.64 130.27 (15048) 131.76 0.64 130.27 (15048) 131.76 (ii) income tax relating to items that will not be reclassified to profit or loss b) (i) items that will be reclassified to profit or loss (ii) income tax relating to items that will be reclassified to profit or loss Total other comprehensive incomel (loss), net of income tax 0,64 130,27 (15.48) 131,76 0,64 130,27 (15.48) 131,76 14 Total comprehensive incomel (Loss) for the period (12+13) 1,194,36 3,396,56 (256,02) 3,593,76 323,08 2,714,21 (584,70) 1,127,67 15 Paid-up equity share capital 5,988.52 5,988.52 5,988.52 5,988.52 5,988.52 5,988.52 5,988.52 5,988.52 (Including Shares pending allotment on account of Merger) Other Equity 1,58,679,07 1,50,442.18 Face value per share (Rs) 10.00 10.00 10.00 10.00 10.00 10,00 10.00 10.00 16 Earnings per equity share ': -Basic (Rs.) 1.99 5045 (0040) 5.78 0.54 4,31 (0,95) 1,66 -Diluted (Rs,) 1.99 5045 (0040) 5.78 0.54 4.31 (0.95) 1.66 , , EPS for the quarters are not annualised Statement of Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026 (Contd ... ) Orchid Pharma Limited Statement of Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026 (Contd ... ) Notes: The above results for the quarter ended June 30, 2026 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on August 14, 2026.The statutory auditors of the company have expressed an unmodified conclusion on the unaudited Standalone and Consolidated resutts The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable. a)The Government of India had consolidated 29 existing labour legislations Into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes', which became effective from 21st November 2025. However, the new Rules are yet to be [Showing first 8,000 characters — download PDF for full document]